Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?

US FDA worries Indivior's formulation in prefilled syringes could lead to adverse events if patients obtain direct access; advisory committee to consider if REMS requiring administration by healthcare providers is adequate.

Syringes stuck in a dartboard

More from US FDA Performance Tracker

More from Regulatory Trackers